Source-grounded facts extracted from Stablecoin Development Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Stablecoin Development Corp reported that prior financial statements should not be relied upon.
“On April 27, 2026, the audit committee of the board of directors and management of the Company concluded that the Company’s previously issued audited consolidated financial statements for the year ended December 31, 2025, should no longer be relied upon because of an error in the Company’s accounting relating to certain outstanding pre-funded warrants issued on October 16, 2025”
Stablecoin Development Corp: Amended and restated bylaws solely to reflect the corporate name change, effective April 2, 2026 (effective 2026-04-02).
“The Board also approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”), solely to reflect the Name Change. The Amended and Restated Bylaws will also become effective as of April 2, 2026.”
Stablecoin Development Corp: Amended certificate of incorporation to change corporate legal name from NovaBay Pharmaceuticals, Inc. to Stablecoin Development Corporation, effective April 2, 2026 (effective 2026-04-02).
“On March 17, 2026, the Board approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) changing the Company’s corporate legal name from “NovaBay Pharmaceuticals, Inc.” to “Stablecoin Development Corporation” (the “Name Change”), to be effective as of April 2, 2026.”
Stablecoin Development Corp: Amended certificate of incorporation to remove prohibition against stockholder action by written consent, exculpate officers, and increase authorized common shares from 1.5 billion to 5 billion (effective 2026-03-12).
“The Second Amended and Restated Certificate of Incorporation reflects changes to the following provisions of the Company’s previous amended and restated certificate of incorporation (the “Prior Charter”) (i) to remove the prohibition against stockholder action by written consent; (ii) to exculpate officers from monetary damages to the fullest extent under applicable law in limited circumstances; and (iii) to provide that the Company is authorized to issue a total of 5,000,000,000 shares of common stock, par value $0.01 per share (the “Common Stock”).”
Stablecoin Development Corp: Amended certificate of incorporation to effect a 1-for-5 reverse stock split (effective 2026-02-20).
“On February 20, 2026, NovaBay Pharmaceuticals, Inc. (the “Company”) filed a certificate of amendment (“Certificate of Amendment”) providing for an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”), to effect a reverse stock split at a ratio of 1-for-5 (the “Reverse Stock Split”).”
Stablecoin Development Corp engaged CBIZ CPAs, P.C. as its auditor.
“On January 30, 2026, with the approval of the Audit Committee, CBIZ CPAs, P.C. (“CBIZ”) was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Stablecoin Development Corp entered into ATM Sales Agreement with Virtu Americas LLC valued at up to $100,000,000 of common stock; commission 2.0% (effective 2026-01-20).
“On January 20, 2026, NovaBay Pharmaceuticals, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with Virtu Americas LLC (“Virtu”), pursuant to which the Company may offer and sell shares of its common stock, par value $0.01 per share (“Common Stock”), having an aggregate offering price of up to $100.0 million from time to time through or to Virtu as its sales agent or principal.”
Stablecoin Development Corp entered into Securities Purchase Agreement with R01 Fund LP, Framework Ventures IV L.P., Tether Investments, S.A. de C.V. and Sky Frontier Foundation valued at aggregate gross proceeds of approximately $134 million (effective 2026-01-16).
“On January 16, 2026, NovaBay Pharmaceuticals, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “SPA”) with each of R01 Fund LP, Framework Ventures IV L.P., Tether Investments, S.A. de C.V. and Sky Frontier Foundation (together, the “Purchasers”).”
Stablecoin Development Corp: Amendment to Certificate of Incorporation to increase authorized capital stock to 1,505,000,000 shares total (1,500,000,000 common, 5,000,000 preferred) (effective 2025-10-16).
“On October 16, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which became effective upon filing. The amendment was approved by the Board and subsequently approved by the Company’s stockholders at the Annual Meeting of Stockholders held on October 16, 2025. The Certificate of Amendment amends Paragraph A of Article IV of the Company’s Amended and Restated Certificate of Incorporation to provide that the Company is authorized to issue a total of 1,505,000,000 shares of capital stock, consisting of 1,500,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par value $0.01 per share.”
Stablecoin Development Corp underwent a change of control involving R01 and Framework.
“As a result of the transactions described in Item 3.02 above, a change of control of the Company occurred, as R01 and Framework each beneficially own 45.1% of outstanding common stock.”
Stablecoin Development Corp: Filed Series D and Series F Certificates of Designation with Delaware Secretary of State to establish preferences and rights of newly created preferred stock series (effective 2025-08-19).
“Before the First Closing described in Item 1.01 above, on August 19, 2025, the Company filed the Series D Certificate of Designation and the Series F Certificate of Designation with the Secretary of State of Delaware setting forth the powers, preferences, rights, qualifications, limitations and restrictions applicable to the Series D Preferred Stock and the Series F Preferred Stock, respectively”
Stablecoin Development Corp received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).
“April 18, 2024, NovaBay Pharmaceuticals, Inc. (the “ Company ”) received a notification (“ Deficiency Letter ”) from the NYSE American LLC (the “ NYSE American ”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “ Company Guide ”) requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses”
Stablecoin Development Corp completed a disposition involving New Age Investments LLC for $1,070,000 (closed 2024-03-25).
“14, 2024. Pursuant to the Purchase Agreement, the Company sold 100% of the membership units (the “ Membership Units ”) of DERMAdoctor to Buyer for a closing purchase price of $1,070,000, as adjusted for the payment of certain outstanding DERMAdoctor indebtedness and transaction expenses. The closing of the DERMAdoctor Sale Transaction was subject to certain”
Stablecoin Development Corp incurred convertible notes of $525,000.
“on March 25, 2024, the Company issued the New Notes having an aggregate principal amount of $525,000 or will be convertible into an aggregate of 3,750,000 shares of Common Stock.”
Stablecoin Development Corp reported preliminary financial results for three and twelve months ended December 31, 2023.
“On March 14, 2024, the Company issued a press release announcing that it had entered into the Purchase Agreement and regarding its results for the three and twelve months ended December 31, 2023.”
Stablecoin Development Corp entered into Membership Unit Purchase Agreement with New Age Investments LLC valued at $1,070,000 (effective 2024-03-12).
“On March 12, 2024, NovaBay Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into a Membership Unit Purchase Agreement (the “ Purchase Agreement ”) by and among: (i) New Age Investments LLC, a Florida limited liability company (the “ Buyer ”); (ii) DERMAdoctor, LLC, a Missouri limited liability company (“ DERMAdoctor ”); and (iii) the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.